Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 11.4% year on year to $61.05 million. Next quarter’s revenue guidance of $62.8 million underwhelmed, coming in 2.9% below analysts’ estimates. Its GAAP profit of $0.75 per share was 31.5% above analysts’ consensus estimates. Is now the time to buy LMAT? Find out in our full research report (it’s free for active Edge members). LeMaitre (LMAT) Q3 CY2025 Highlights: Revenue: $61.05 ...